Your browser doesn't support javascript.
loading
Platinum sensitivity and CD133 expression as risk and prognostic predictors of central nervous system metastases in patients with epithelial ovarian cancer.
Liu, Bo-Lin; Liu, Shu-Juan; Baskys, Andrius; Cheng, Hong; Han, Ying; Xie, Chao; Song, Hui; Li, Jia; Xin, Xiao-Yan.
Afiliação
  • Baskys A; Department of Obstetrics and Gynecology, Xijing Hospital, Fourth Military Medical University, West Changle Road, No,127, Xi'an 710032 Shaanxi Province People's Republic of China. abaskys@ucr.edu.
BMC Cancer ; 14: 829, 2014 Nov 17.
Article em En | MEDLINE | ID: mdl-25399490
ABSTRACT

BACKGROUND:

To characterize prognostic and risk factors of central nervous system (CNS) metastases in patients with epithelial ovarian cancer (EOC).

METHODS:

A retrospective analysis of Xijing Hospital electronic medical records was conducted to identify patients with pathologically confirmed EOC and CNS metastases. In addition to patient demographics, tumor pathology, treatment regimens, and clinical outcomes, we compared putative cancer stem cell marker CD133 expression patterns in primary and metastatic lesions as well as in recurrent EOC with and without CNS metastases.

RESULTS:

Among 1366 patients with EOC, metastatic CNS lesions were present in 29 (2.1%) cases. CD133 expression in primary tumor was the only independent risk factor for CNS metastases; whilst the extent of surgical resection of primary EOC and platinum resistance were two independent factors significantly associated with time to CNS metastases. Absence of CD133 expression in primary tumors was significantly associated with high platinum sensitivity in both patient groups with and without CNS metastases. Platinum resistance and CD133 cluster formation in CNS metastases were associated with decreased survival, while multimodal therapy including stereotactic radiosurgery (SRS) for CNS metastases was associated with increased survival following the diagnosis of CNS metastases.

CONCLUSIONS:

These data suggest that there exist a positive association between CD133 expression in primary EOC, platinum resistance and the increased risk of CNS metastases, as well as a less favorable prognosis of EOC. The absence of CD133 clusters and use of multimodal therapy including SRS could improve the outcome of metastatic lesions. Further investigation is warranted to elucidate the true nature of the association between platinum sensitivity, CD133 expression, and the risk and prognosis of CNS metastases from EOC.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Ovarianas / Peptídeos / Glicoproteínas / Antígenos CD / Neoplasias do Sistema Nervoso Central / Compostos de Platina / Neoplasias Epiteliais e Glandulares / Resistencia a Medicamentos Antineoplásicos Tipo de estudo: Diagnostic_studies / Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Aged / Female / Humans / Middle aged Idioma: En Ano de publicação: 2014 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Ovarianas / Peptídeos / Glicoproteínas / Antígenos CD / Neoplasias do Sistema Nervoso Central / Compostos de Platina / Neoplasias Epiteliais e Glandulares / Resistencia a Medicamentos Antineoplásicos Tipo de estudo: Diagnostic_studies / Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Aged / Female / Humans / Middle aged Idioma: En Ano de publicação: 2014 Tipo de documento: Article